Analysts expect Serina Therapeutics, Inc. to report revenue of 0.00 for Q3 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 130,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -23,092.98 | -9,640.79 | -4,269.65 | -23,817.66 | ||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -26,072.24 | -10,547.59 | -4,589.31 | -25,940.12 | ||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -24,582.61 | -10,094.19 | -4,429.48 | -24,878.89 |
Analysts expect Serina Therapeutics, Inc. to report earnings per share of -0.36 for Q3 26, against a range of -0.39 to -0.33. The most recent reported quarter, Q2 26, came in at -0.55, a 22.2% miss against the -0.45 consensus.
| Metric | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.49 | -0.66 | -0.45 | -0.31 | -0.58 | -0.55 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.56 | -0.43 | -0.47 | -0.50 | -0.41 | -0.41 | -0.33 | -0.29 | -0.25 | -0.26 | -0.17 | -0.15 | -0.34 | -0.33 | ||||||||||
| Low Estimate | -0.60 | -0.47 | -0.55 | -0.56 | -0.45 | -0.49 | -0.39 | -0.35 | -0.29 | -0.32 | -0.19 | -0.17 | -0.40 | -0.37 | ||||||||||
| Consensus Estimate | -0.58 | -0.45 | -0.51 | -0.53 | -0.43 | -0.45 | -0.36 | -0.32 | -0.27 | -0.29 | -0.18 | -0.16 | -0.37 | -0.35 |